tbuckley/cabot-search huggingface dataset:
Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging.
Authors: P Bolufer, E Ricart, A Lluch, C Vazquez, A Rodriguez, A Ruiz, F Llopis, J Garcia-Conde, R Romero
Journal: Journal of Clinical Oncology (1992)

PURPOSE The present report attempts to clarify whether there is a relationship between aromatase activity (ARAC) and estradiol (E2), hormonal receptors, E2 receptor (ER), and epidermal growth factor receptor (EGFR), as well as with tumor stage and histopathology in human breast cancers. MATERIALS AND METHODS We studied 225 breast carcinomas, 67 of which were premenopausal and 158 postmenopausal. In each sample, ARAC, EGFR, ER, and E2 were quantified. ARAC was quantified by Thompson and Siiterii's method, EGFR was quantified with a two-point assay method using radioactive iodine (125I)-EGF as ligand, and ER was measured by the Scatchard method using 3H-E2. E2 was quantified by radioimmunoassay in the diethylether tumor extract. RESULTS ARAC was found in 64% of the cancers studied. There is a strong direct association between ARAC and tumor size in postmenopausal patients (P = .001). In the postmenopausal group, the proportion of ARAC-positive (ARAC+) tumors is significantly higher among ER-positive (ER+) than ER-negative (ER-) ones (P less than .001). ER+ tumors also have significantly higher levels of E2 than do ER- ones (P less than .0001); similarly, ARAC+ tumors have significantly higher levels of E2 than do ARAC- ones (P less than .0001). There is a significant multiple linear correlation between the log of the levels of ARAC, ER, and EGFR and the log of tumor E2 (P less than .0001). The correlation coefficients obtained show that ARAC and ER have a positive effect on tumor E2. CONCLUSION The results obtained suggest the importance of tumor ARAC in the tumoral levels of E2 and reinforce the possible biologic significance of tumor ARAC, especially in postmenopausal breast carcinoma patients.
Reflections on 2004 and plans for 2005
Authors: R C Spiller
Journal: Gut (2004)

The December issue is a good time to reflect on the past year’s achievements and to look forward to the New Year: 2004 was a bumper year for Gut with over 1900 manuscripts submitted for publication. Over the last two years we have seen submissions rise by nearly a third but in spite of this we have maintained and, more recently, reduced the all important median time to first decision which is now 13 days. Most manuscripts go out to review within nine days and the average time to receive two complete reviews is 22 days. A streamlined decision process allows a final decision, on average, nine days from receipt of review. Once a manuscript is accepted, the next important date is publication, and we have worked hard to reduce this delay, which is frustrating for authors. We set ourselves a goal of reducing the time from acceptance to publication to four months. A manuscript accepted in December can expect to go to print within …
Clinical characteristics, treatment and survival outcomes in malignant mesothelioma
Authors: Serdar Berk, Ömer Tamer Dogan, Saadettin Kiliçkap, Kürsat Epöztürk, Ibrahim Akkurt, Zehra Seyfikli
Journal: European Respiratory Journal (2012)

Objective: We aimed to evaluate the clinical, radiological and survival features of patients with MM.

Methods: The study included 228 patients who were followed up in our center between 1993 and 2010 with the diagnosis of MM.

Results: The mean age was 59.1 years in men and 58.7 years in women (male/female=1.4). Environmental asbestos exposure was present in 86% of the patients for a mean duration of 40±20 years. Closed pleural needle biopsy was the most common diagnostic procedure (56.4%). One hundred-thirteen (66%) patients were treated with platinum-based combination chemotherapy (PBCT) plus supportive care (SC) and 67 (34%) patients received SC alone.

![Figure][1] 



The median follow-up time was 10.0 months. The median overall survival was significantly improved with PBCT plus SC compared to SC alone (11.4 vs. 5.1 months; p= 0.005). The 6, 12, 18, and 24-month survival rates were significantly improved with PBCT plus SC compared to SC alone (72%, 43%, 19%, and 2% vs. 49%, 31%, 11%, and 1%).

![Figure][1] 



Conclusion : The survival of patients with MM improved in patients treated with PBCT. The survival advantage continued 12- and 24-month after the initial time of combination chemotherapy.

 [1]: pending:yes
Vitamin D, exacerbations and hospitalizations in COPD patients
Authors: Michela Bellocchia, Monica Masoero, Arianna Vaudano, Antonio Ciuffreda, Andrei Malinovschi, Caterina Bucca
Journal: European Respiratory Journal (2013)

COPD has heavy influence on healthcare costs, due to frequent exacerbations and hospital admissions. Vitamin D is involved in immunity regulation, and its deficiency is associated with increased respiratory infections even in normal subjects. We evaluated the relationship between vitamin D and disease severity, FEV1 decline, exacerbations and hospitalization in COPD patients.  Methods- Lung function, comorbidities, nutritional status, FEV1 decline, number of exacerbations and hospitalizations in the previous year, were recorded in 97 COPD patients, 44 men, 62 current smokers  Results. GOLD distribution: class 1:17%, class 2:60%, class 3:19%, class 4:3%. Vitamin D deficiency was found in almost all the patients and was severe (  Conclusion. Severe vitamin D deficiency is common in COPD patients and increases the risk of frequent exacerbations and hospitalizations. Vitamin D supplementation might reduce healthcare costs of COPD.
A multicenter, open‐label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma
Authors: Chuanying Geng, Jian Hou, Yaozhong Zhao, Xiaoyan Ke, Zhao Wang, Lugui Qiu, Hao Xi, Fuxu Wang, Na Wei, Yan Liu, Shifang Yang, Peng Wei, Xiangjun Zheng, Zhongxia Huang, Bing Zhu, Wen‐Ming Chen
Journal: American Journal of Hematology (2014)

Circularly permuted TRAIL (CPT), a recombinant mutant of human Apo2L/TRAIL, is a novel antitumor candidate for multiple myeloma (MM) and other hematologic malignancies. In this phase II study, the safety and efficacy of CPT plus thalidomide was investigated in thalidomide-resistant MM patients. A total of 43 patients were recruited into three CPT plus thalidomide cohorts based on CPT dosage in sequence: 5 mg/kg (n = 11), 8 mg/kg (n = 17), and 10 mg/kg (n = 15). CPT was administered via intravenous infusion on days 1-5, and thalidomide was given orally at 100 mg once daily in each 21-day cycle. The overall response rate (ORR) of 41 efficacy-evaluable patients was 22.0% (2 complete response, 3 near complete response, and 4 partial response). No significant difference in the ORR was observed among the three dose cohorts; however, the ORR tended to be higher with the higher-dose regimen. Median progression-free survival and median duration of response were 6.6 months and 6.1 months, respectively. The most common treatment-related adverse events (TRAEs) were neutropenia (46.5%), leukopenia (41.9%), fever (37.2%), elevated AST (32.6%), and elevated ALT (20.9%). TRAEs of Grade 3-4 were mainly neutropenia (18.6%), anemia (9.3%), elevated AST (7.0%), and leukopenia (4.7%). No significant differences were found in the incidence and severity of TRAEs among the three cohorts. In conclusion, CPT plus thalidomide was well tolerated with no occurrence of dose-limiting toxicities and demonstrated promising antitumor activity in RRMM patients. CPT at 10 mg/kg for 5 days in combination with thalidomide and dexamethason will be studied in the next clinical trial.
Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal Insufficiency Undergoing Coronary Angiography
Authors: Sang-Ho Jo, Tae-Jin Youn, Bon-Kwon Koo, Jin-Shik Park, Hyun-Jae Kang, Young-Seok Cho, Woo-Young Chung, Gwon-Wook Joo, In-Ho Chae, Dong-Ju Choi, Byung-Hee Oh, Myoung-Mook Lee, Young-Bae Park, Hyo-Soo Kim
Journal: Journal of the American College of Cardiology (2006)
Advanced glycation end products and its soluble receptor (sRAGE) are increased in chronic heart failure but not in chronic obstructive pulmonary disease
Authors: Piera Boschetto, Ilaria Campo, Mariarita Stendardo, Enrico Casimirri, Carmine Tinelli, Claudio Ceconi, Alessandro Fucili, Alfredo Potena, Licia Ballerin, Leonardo M. Fabbri, Maurizio Luisetti
Journal: European Respiratory Journal (2012)

The binding of the receptor for advanced glycation end products (RAGE) with its ligands begins a cellular activation and an inflammatory signal amplification in different diseases.  We determined the plasma levels of N(epsilon)-carboxymethyllysine (CML) and soluble RAGE (sRAGE) in chronic heart failure (CHF) patients, in cases with chronic obstructive pulmonary disease (COPD) and in healthy controls. We also investigated the associations between these biomarkers and the clinical and functional characteristics of the study populations.  The CML and sRAGE plasma levels were measured by using a sandwich enzyme-linked immunosorbent assay (ELISA) in 146 subjects, aged ≥ 65 years, divided into five groups: 58 with CHF, 23 with COPD, 29 with CHF and COPD and 36 controls (18 current or former smokers, and 18 never smokers). Individuals with diabetes were excluded from this study.  The CML and sRAGE levels were higher in CHF patients than in controls [CML: 1.9 (1.5-2.4) vs 1.6 (1.4-2.0) ng/mL; sRAGE: 0.51 (0.3-0.8) vs 0.41 (0.3-0.5) ng/mL; p=0.01]. By contrast, both CML and sRAGE were not different when the group with COPD and that with CHF/COPD were compared with controls (p>0.05). sRAGE positively correlated with N-terminal proBNP (Nt-Pro BNP) in the three patient groups: CHF (r=0.43, p  In conclusion, subjects with CHF have high plasma levels of CML and sRAGE. The robust asociation between sRAGE and NT-proBNP concentrations might suggest a potential diagnostic and prognostic significance of this receptor in heart failure.  Supported by the Italian Ministry of Health.
Primary Systemic Therapy in Operable Breast Cancer
Authors: Antonio C. Wolff, Nancy E. Davidson
Journal: Journal of Clinical Oncology (2000)

PURPOSE: Laboratory studies suggest that primary systemic therapy (PST) could improve control of micrometastatic disease and impact on overall survival (OS). This article examines the rationale for and preclinical and clinical data of PST in operable breast cancer and the potential role of intermediate biomarkers as predictive and/or prognostic factors for response and survival. DESIGN AND METHOD: We conducted an extensive literative review (including MEDLINE) on preclinical studies, single-arm feasibility studies, large randomized single- and multi-institutional trials, and laboratory correlate studies of PST in breast cancer. RESULTS: Small trials in locally advanced disease showed high initial rates of response and local control. Six randomized clinical trials (RCTs) of PST for palpable, operable breast cancer have been reported since 1991 (from 204 to 1,523 patients each). These data clearly show a small but significant (less than 10%) absolute increase in the use of breast-conservation treatment (BCT) with similar rates of local control. Although one study showed better disease-free survival (DFS) and another showed better OS, most studies did not show any survival advantage of primary versus adjuvant systemic therapy. Thus far, pathologic complete response seems to be the best predictor of survival, but clinical response assessment correlates poorly with pathologic response. Pilot studies demonstrated feasibility of procuring tissue at diagnosis and after treatment for assays of potential intermediate biomarkers. Initial data suggest a potential correlation between markers of proliferation and apoptosis and in vivo chemotherapy sensitivity. CONCLUSION: Thus far, RCTs of PST versus standard adjuvant therapy have not shown any clear benefit for DFS or OS in early breast cancer. Ongoing trials should determine if specific subsets of patients at risk would benefit from additional systemic therapy and the potential role of intermediate biomarkers in identifying such women. Although PST results in a small increase in the rate of BCT with similar rates of local control, current PST strategies should not replace standard adjuvant approaches. Rather, they represent an acceptable alternative to women with palpable, operable tumors and an excellent arena for clinical trials.
Mutation analysis (<i>ABCC6</i>) in a family with pseudoxanthoma elasticum: presymptomatic testing with prognostic implications
Authors: Q. Li, L. Török, L. Kocsis, J. Uitto
Journal: British Journal of Dermatology (2010)

Conflicts of interest: none declared. Madam, Pseudoxanthoma elasticum (PXE) is a multisystem disorder characterized by ectopic mineralization of extracellular matrix of connective tissues (reviewed1). The disease primarily affects the skin, the eyes and the cardiovascular system, with considerable morbidity and occasional mortality. The characteristic skin manifestations, i.e. yellowish papules, which tend to coalesce into larger inelastic plaques on the predilection sites, are primarily of cosmetic concern, but they imply the risk for development of serious ocular and vascular complications. PXE is caused by mutations in the ABCC6 gene which encodes a transmembrane transporter expressed primarily in the liver and kidneys.2 The precise functions of this transporter under physiological conditions and its ligand molecules in vivo are currently unknown. It has been suggested, however, based largely on animal studies utilizing an Abcc6'knock‐out' mouse as a model system, that PXE is a metabolic disorder which in the absence of functional ABCC6 transporter activity results in deficiency of antimineralization factors in the circulation.3 This situation then allows progressive mineralization of the peripheral connective tissues to ensue.
Detection of circulating tumor cells in men with localized prostate cancer.
Authors: M V Seiden, P W Kantoff, K Krithivas, K Propert, M Bryant, E Haltom, L Gaynes, I Kaplan, G Bubley, W DeWolf
Journal: Journal of Clinical Oncology (1994)

Using prostate-specific antigen (PSA) mRNA as a marker for prostatic epithelial cells, we have developed a sensitive technique that involves reverse transcription and polymerase chain reaction (RT-PCR) to detect circulating tumor cells in the peripheral blood of men with prostatic carcinoma (CaP).A sensitive RT-PCR assay was used to evaluate the peripheral blood of 135 men with a history of CaP. Fourteen men with benign prostate disease, many of whom had elevated serum PSA levels, were used as a control group.All patients with benign prostate disease had a negative result in the RT-PCR assay. Of particular interest was a subgroup of 65 patients with clinically localized CaP evaluated before definitive local therapy. Five of these patients had detectable PSA mRNA by RT-PCR, suggesting circulating tumor cells. Within this group, systemic disease was detected by RT-PCR in some men with PSA levels less than 10 ng/mL and clinical stage B disease. Blood from men with hormone-refractory and progressive CaP demonstrated a higher frequency of PSA mRNA detectable by RT-PCR (10 of 20 patients). In contrast, none of seven patients with newly diagnosed metastatic prostate cancer and only one of seven patients with metastatic, hormone-responsive disease had blood that was positive for PSA mRNA by RT-PCR.Circulating tumor cells can be detected in the blood of a subset of patients with clinically localized CaP and a larger subset of patients with progressive metastatic disease.
Influence of the interface on the use of positive expiratory pressure (PEP) device
Authors: Grégory Reychler, Thibault Coppens, Jean Roeseler, Pierre Delguste, Giuseppe Liistro
Journal: European Respiratory Journal (2011)

Introduction:  Positive expiratory pressure (PEP) is regularly used as airway clearance technique. PEP devices provide constant back pressure to the airways during expiration. To be efficient, this pressure must be maintained up to 10 cm H 2 O. Facemask and mouthpiece are used with these devices. The aim of this study was to observe the influence of the interface on generated pressure.   Material and method:  Seven healthy subjects were recruited (26.7 yrs.± 6.0). They were instructed to breathe through a PEP device (PARI PEP S) according to the recommendations. Two interfaces (mouthpiece and facemask) and 4 different calibrated resistances were used in a randomized crossover design. Continuous recordings of airway pressure and airflow were performed. Sequence was composed by 5 breathes at 4 different resistances (2mm, 3mm, 4mm, 5mm). Success rate was defined as an expiratory pressure higher than 10cm H 2 O.   Results:  Depending on interface, significant differences (mouthpiece vs. facemask) were measured for Pe max (16.6cm H 2 O±15.8 vs. 11.2cm H 2 O±5.9; p 2 O±7.5 vs. 7.8cm H 2 O±3.7; p 10cm H 2 O (6.05s±7.75 vs. 3.88s±6.73; p=0.006) and inspiratory (3.65s±1.61 vs 4.32s±1.87; p   Conclusion:  Interface influences the expiratory pressure but the success rate is not modified.
Elimination of symbiotic Aeromonas spp. from the intestinal tract of the medicinal leech, Hirudo medicinalis, using ciprofloxacin feeding
Authors: K.Y. Mumcuoglu, L. Huberman, R. Cohen, V. Temper, A. Adler, R. Galun, C. Block
Journal: Clinical Microbiology and Infection (2009)
Mapping Molecular Networks Using Proteomics: A Vision for Patient-Tailored Combination Therapy
Authors: Emanuel F. Petricoin, Verena E. Bichsel, Valerie S. Calvert, Virginia Espina, Mary Winters, Lynn Young, Claudio Belluco, Bruce J. Trock, Marc Lippman, David A. Fishman, Dennis C. Sgroi, Peter J. Munson, Laura J. Esserman, Lance A. Liotta
Journal: Journal of Clinical Oncology (2005)

Mapping tumor cell protein networks in vivo will be critical for realizing the promise of patient-tailored molecular therapy. Cancer can be defined as a dysregulation or hyperactivity in the network of intracellular and extracellular signaling cascades. These protein signaling circuits are the ultimate targets of molecular therapy. Each patient's tumor may be driven by a distinct series of molecular pathogenic defects. Thus, for any single molecular targeted therapy, only a subset of cancer patients may respond. Individualization of therapy, which tailors a therapeutic regimen to a tumor molecular portrait, may be the solution to this dilemma. Until recently, the field lacked the technology for molecular profiling at the genomic and proteomic level. Emerging proteomic technology, used concomitantly with genomic analysis, promises to meet this need and bring to reality the clinical adoption of molecular stratification. The activation state of kinase-driven signal networks contains important information relative to cancer pathogenesis and therapeutic target selection. Proteomic technology offers a means to quantify the state of kinase pathways, and provides post-translational phosphorylation data not obtainable by gene arrays. Case studies using clinical research specimens are provided to show the feasibility of generating the critical information needed to individualize therapy. Such technology can reveal potential new pathway interconnections, including differences between primary and metastatic lesions. We provide a vision for individualized combinatorial therapy based on proteomic mapping of phosphorylation end points in clinical tissue material.
Diphenylcyclopropenone in patients with alopecia areata. A critically appraised topic
Authors: R.A. Kuin, P.I. Spuls, J. Limpens, E. J. van Zuuren
Journal: British Journal of Dermatology (2015)

Journal Article Diphenylcyclopropenone in patients with alopecia areata. A critically appraised topic Get access R.A. Kuin, R.A. Kuin Dutch Association for Dermatology and Venereology (NVDV) Utrecht the Netherlands Search for other works by this author on: Oxford Academic Google Scholar P.I. Spuls, P.I. Spuls Dermatology Department Academic Medical Center Amsterdam the Netherlands Search for other works by this author on: Oxford Academic Google Scholar J. Limpens, J. Limpens Academic Medical Center Amsterdam the Netherlands Search for other works by this author on: Oxford Academic Google Scholar E. J. van Zuuren E. J. van Zuuren Dermatology Department Leiden University Medical Center Leiden the Netherlands Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 173, Issue 4, 1 October 2015, Pages 896–909, https://doi.org/10.1111/bjd.14040 Published: 01 October 2015
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
Authors: J L Finlay, S Goldman, M C Wong, M Cairo, J Garvin, C August, B H Cohen, P Stanley, R A Zimmerman, B Bostrom, J R Geyer, R E Harris, J Sanders, A J Yates, J M Boyett, R J Packer
Journal: Journal of Clinical Oncology (1996)

PURPOSE This study was designed to determine the toxicity, radiographic response rate, and outcome following high-dose thiotepa, etoposide, and autologous bone marrow rescue (ABMR) for young patients with recurrent malignant brain tumors. METHODS Eligibility criteria required adequate renal, hepatic, and pulmonary function, and no bone marrow infiltration. Thiotepa 300 mg/m2 and etoposide 500 mg/ m2 were infused on 3 consecutive days, and autologous bone marrow was infused 72 hours following chemotherapy. RESULTS Forty-five patients with recurrent high-grade brain tumors, aged 8 months to 36 years (median, 8 years), were treated. Seven patients (16%) died of treatment-related toxicities within 56 days of marrow reinfusion. Delayed platelet engraftment occurred in 44% of patients who survived beyond day 56. Of 35 patients with radiographically measurable disease who survived at least 28 days following ABMR, there were two complete responses (CRs) and six partial responses (PRs), for an overall response (CRs plus PRs) rate of 23% (SE = 7%). Objective responses were observed in four of 14 assessable patients with high-grade glioma and in two of six with primitive neuroectodermal tumors (PNETs)/ medulloblastoma. Survival was significantly improved in patients treated with minimal residual disease (P &lt; .0005). Five of 18 patients (28%) with high-grade gliomas remain free of disease at 39+, 44+, 49+, 52+, and 59+ months post-ABMR. CONCLUSION The combination of high-dose thiotepa and etoposide has activity against a variety of recurrent childhood brain tumors. These results merit further evaluation in children and young adults with both recurrent and newly diagnosed high-grade brain tumors.
Brief Communication : G- and C-Banding Patterns in the T2 Murine Leukemia 2
Authors: Martha S. Bianchi, Susana Merani, N. O. Bianchi
Journal: JNCI Journal of the National Cancer Institute (1975)

The bone marrow cells of BALB/c mice with T2 murine leukemia were analyzed cytogenetically. Of 98 leukemia metaphases, 16.3% were hypodiploid, 4.1% hyperdiploid, and 79.5% diploid. The distribution of G bands in diploid metaphases indicated that almost half of them were pseudodiploid, with chromosome abnormalities such as trisomies, monosomies, nullisomies, unidentified chromosomes, translocations, deletions, or duplications. Since all mouse chromosomes are acrocentric and can be identified only tentatively most of the anomalies detected with G-banding procedures would have passed unnoticed with conventional cytogenetic techniques. The C-banding pattern of leukemia cells did not differ from that of normal controls. However, a considerable number of leukemia cell metaphases had bridges connecting the centromeric C bands of two or more chromosomes. This phenomenon probably indicates an increased stickiness of the heterochromatin, which may produce mitotic nondisjunction and the appearance of monosomies and trisomies.